Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015

Volume 4, Issue 3, Part 1.

Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Vincent Leroy from Grenoble University Hospital about the ALLY-3+ study.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 3.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 2.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION

Special Edition 2014, Issue 2, Part 1.

Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indiana University School of Medicine about HCV-HIV coinfection, decompensated cirrhosis, liver transplantation and discusses strategies to treat this hard-to-treat patient subpopulation with program director, Dr. Mark Sulkowski.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY

Special Edition 2014, Issue 1, Part 2.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore discusses patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy with program director, Dr. Raymond Chung.

INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY

Special Edition 2014, Issue 1, Part 1.

Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore interviews Dr. David Nelson from the University of Florida about patients who have genotype 3 or cirrhosis, are interferon-ineligible/intolerant, or have failed previous therapy.

Highlights from the 2014 EASL Meeting

Volume 3, Issue 12.

Mark S. Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins University School of Medicine, Raymond T. Chung, Associate Professor of Medicine, Harvard Medical School, Director of Hepatology, Vice Chief of Gastroenterology at Massachusetts General Hospital, and Laurent Castera, MD, PhD, Department of Hepatology, Beaujon Hospital, AP-AP, INSERM U773 at the University of Paris-Diderot. Discuss new information presented at the 2014 European Association for the Study of the Liver (EASL) meeting, as well as non-invasive markers of liver disease.

HCV Screening and Natural History

Volume 3, Issue 10.

David Thomas, MD, Professor of Medicine, and Director of the Division of Infectious Diseases at the Johns Hopkins University School of Medicine discusses HCV screening and natural history, in the form of case-study scenarios for the clinical practice.

Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD

Volume 3, Issue 8.

Susanna Naggie, MD, Professor, Assistant Professor of Medicine, Department of Medicine – Infectious Diseases at Duke University School of Medince discusses the development of new therapies for treating hepatitis C infection, and news about hepatitis B from the 64th meeting of the American Association for the Study of Liver Disease, as well as case-study scenarios for the clinical practice.